F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
F. Hoffmann-La Roche Ltd. has divulged pyrimidin-2-yl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists reported to be useful for the treatment of obesity, Alzheimer's disease, Parkinson's disease, meningitis, encephalitis, ischemia, demyelinating diseases and schizophrenia.
F. Hoffmann-La Roche Ltd. has discovered benzothiazolyl bicyclo[1.1.1]pentane derivatives acting as hepatitis B virus (HBV) HBeAg and HBsAg secretion inhibitors, reported to be useful for the treatment of HBV infections.
